Regeneron Pharmaceuticals Inc. buy stratec
Start price
08.11.17
/
50%
€377.04
Target price
04.11.21
€560.00
Performance (%)
48.53%
End price
05.11.21
€560.00
Summary
This prediction ended on 05.11.21 with a price of €560.00. With a performance of 48.53% the BUY prediction by stratec was a big success. stratec has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.340% | -0.340% | 22.275% | -13.579% |
| iShares Core DAX® | 0,85 % | 0,39 % | 2,53 % | 52,00 % |
| iShares Nasdaq 100 | -0,99 % | -4,40 % | 25,15 % | 77,54 % |
| iShares Nikkei 225® | -1,78 % | -11,22 % | 44,40 % | 64,68 % |
| iShares S&P 500 | 0,06 % | 0,78 % | 20,95 % | 63,01 % |
Comments by stratec for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
stratec stimmt der Buy-Einschätzung von melinda zu
stratec stimmt am 08.11.2017 der Buy-Einschätzung von melinda mit dem Kursziel 560$ zu.Überschrift: Raymond James Surpasser 566 $
Kursziel geändert auf 405,12
Kursziel geändert auf 470,0
Kursziel geändert auf 560,0
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten